

# The promise of Interleukin-2 Therapy

For autoimmune and inflammatory diseases, allergy, transplantation and cancer

Centre International de Congrès – Sorbonne Université  
75005 Paris  
November 13-16

## International Organizing Committee

Abul Abbas, Christophe Benoist, David Klatzmann (Chair), Thomas Malek, Georges Tsokos

## Local Organizing Committee (iMAP)

Caroline Aheng, Véronique Dhennin, Dusko Ehrlich, Emmanuel Gautherot, Véronique Gesqua, Sophie Harris, Emmanuelle Le Chatelier, Jérémie Mariau, Encarnita Marriotti-Ferrandiz, Ivan Moszer, Michelle Rosenzweig

## Confirmed Speakers (*in alphabetical order*)

Abul K. Abbas, Andre Ballesteros-Tato, Christophe Benoist, Jeffrey Bluestone, Onur Boyman, Michael Farrar, Jason Fontenot, Jens Humrich, John Koreth, David Klatzmann, Vijay Kuchroo, Mike Leonardo, Claude Le Pen, Zhanguo Li, Thomas Malek, Robert Plenge, Jerome Ritz, Michelle Rosenzweig, Alberto Sanchez-Fueyo, Scott Snapper, Naomi Taylor, Nadia Tchao, Georges Tsokos, Harikesh Wong, Jonathan Zalevsky



## Wednesday 13

6.00 pm

### Opening Session

Welcome words

- Jean Chambaz, Sorbonne Université President
- Martin Hirsh, Head of AP-HP

### Keynote lectures

Chair: J. Bluestone

- "Tregs today" – A. Abbas
- "IL-2 revival" – D. Klatzmann

8.00 pm

Welcome reception

## Thursday 14

**8.30 am**

### **Session I.a – On mechanistic aspects**

Chair: T. Malek

1. IL-2R-dependant mechanisms in immune tolerance (T. Malek)
2. TBA (M. Leonardo)
3. Talks from abstracts

**10.30 – 11.00 am – Coffee break**

**11.00 am**

### **Session I.b - On mechanistic aspects**

Chair: V. Kuchroo

1. Control of Tfh cell responses by IL-2 (A. Ballesteros-Tato)
2. Induction & effector function of Th17 cells (V. Kuchroo)
3. Talks from abstracts

**1.00 pm – Lunch**

**2.00 pm**

### **Session II – Preclinical research & pharmacology**

Chair: A. Abbas

1. IL-2 in regulatory T cell development and homeostasis (M. Farrar)
2. Local regulatory cell density dictates autoreactive T cell signed integration and fate (H. Wong)
3. Treg activation and energetic and biosynthetic demands (N. Taylor)
4. Talks from abstracts

**4.00 – 4.30 pm – Coffee break**

**4.30 pm**

### **Session III.a - Lessons from current clinical trials with plain IL-2**

Chair: G. Tsokos

1. Low-dose IL-2 Treatment of Sjogren syndrome – a double blind placebo controlled study (Z. Li)
2. Low-dose IL-2 therapy in SLE: results from a single-center phase 1/2 clinical trial (J. Humrich)
3. Low-dose IL2 for the treatment of ulcerative colitis – lessons learned from humanized mice and patients (S. Snapper)
4. Talks from abstracts

**8.00 pm – End of the day**

## Friday 15

**8.30 am**

### **Session III.b - Lessons from current clinical trials with plain IL-2**

Chair: J. Koreth

1. Low-dose IL-2 in chronic GVHD: lessons from 5 trials (J. Koreth)
2. IL-2 & liver transplantation (A. Sanchez-Fueyo)
3. IL-2 in T1D (A. Hartemann)
4. Talks from abstracts

**10.30 – 11.00 am – Coffee break**

**11.00 am**

### **Session IV - From biomarkers to theranostics**

Chair: C. Benoist

1. Systems immunology & drug development (C. Benoist)
2. Effects of daily low dose IL-2 on Treg homeostasis (J. Ritz)
3. Biomarkers of efficacy of IL-2 from clinical trials (M. Rosenzweig)
4. TCRs as biomarkers (E. Mariotti-Ferrandiz)
5. pSTAT5 as biomarkers (T. Miloud)
6. Talks from abstracts

**1.00 pm – Lunch**

**2.00 pm**

### **Session V.a - Novel IL-2s**

Chair: D. Klatzmann

1. AMG 592 is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells (N. Tchao)
2. Talks from abstracts

**4.00 – 4.30 pm – Coffee break**

**4.30 pm**

### **Session VI - IL-2 in cancer therapy**

Chair: O. Boyman

1. TBA (J. Zalevsky)
2. Selective IL-2 Immunotherapy to Fuel the Anti-Tumor Immune Response (O. Boyman)
3. Talks from abstracts

**5.30 pm**

### **Session VII - IL-2 and medico-economic aspects of immunotherapies**

Chair: C. Le Pen

Round Table

**8.00 pm End of the day**

## Saturday 16

**8.30 am**

### **Session VIII - IL-2 and Treg cell therapies: competing or complementing?**

Chair: J. Fontenot

1. The future of Treg therapy (J. Bluestone)
2. CAR-Tregs (J. Fontenot)
3. IL-2 modified Tregs (TBA)
4. *Talks from abstracts*

**10.30 – 11.00 am – Coffee break**

**11.00 am**

### **Session V.b - Novel IL-2s**

Chair: D. Klatzmann

1. Treg expansion via IL-2 mutein (R. Plenge)
2. IL-2/CD25: A long-acting IL-2-based fusion protein that suppresses autoimmunity (J. Bon Lui)
3. Multimeric mutated IL-2 (J. Mariau)
4. *Talks from abstracts*

**1.00 pm Afterwords**